Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

VistaGen Therapeutics Q2 2024 EPS $(0.66) Beats $(0.68) Estimate, Sales $277.70K Beat $180.00K Estimate

Author: Benzinga Newsdesk | November 09, 2023 05:49pm
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.68) by 2.94 percent. This is a 72.5 percent increase over losses of $(2.40) per share from the same period last year. The company reported quarterly sales of $277.70 thousand which beat the analyst consensus estimate of $180.00 thousand by 54.28 percent. This is a 131.11 percent increase over sales of $(892.50 thousand) the same period last year.

Posted In: VTGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist